Anybody who has been watching the omega-3 market knows 2013 was a bad year for fish oil. Headlines questioning the cardiovascular benefits and linking higher omega-3 levels to prostate cancer cast doubt on what had been accepted as a must-take supplement.
NBJ estimates fish oil sales dropped 11 percent in the aftermath.
The question a year later is can the positive headlines undo at least some of the damage. That’s what GOED Executive Director Adam Ismail talked